Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been given an average rating of “Buy” by the five brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating on the company.

A number of equities research analysts recently commented on the company. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Wall Street Zen upgraded Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Zacks Research cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY stock opened at $9.67 on Wednesday. The firm’s 50 day moving average price is $8.21 and its two-hundred day moving average price is $7.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. Bayer Aktiengesellschaft has a 52-week low of $4.79 and a 52-week high of $10.03. The stock has a market cap of $38.00 billion, a PE ratio of -107.43, a PEG ratio of 4.90 and a beta of 0.69.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.